Fairvalue-Calculator Fairvalue-Calculator
EN DE

NanoEcho AB (NANECH) Fair Value & Analysis

Healthcare · SE · Market cap 19.9M SEK

Pricekr 0.0392
Fair Valuekr 0.0317
Upside-19.2%
Quality91/100
Evidence: Low Range kr 0.0317 – kr 0.0356

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

NanoEcho AB (NANECH) currently trades at kr 0.0392, while our model-based Fair Value estimate is kr 0.0317 — implying the stock looks roughly 19.2% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

NanoEcho AB (publ) engages in developing a new diagnostic method to determine the spread of rectal cancer to nearby lymph nodes. The company was incorporated in 2013 and is headquartered in Lund, Sweden.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is NanoEcho AB (NANECH) undervalued?
As of Jun 26, 2026, our model estimates a fair value of kr 0.0317 versus a price of kr 0.0392 — about −19% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NANECH?
Our 21-model fair value for NanoEcho AB is kr 0.0317 (as of Jun 26, 2026), built from audited fundamentals. The current price is kr 0.0392.
What is the quality score of NANECH?
NanoEcho AB has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.